Cellphire Therapeutics
Phase 2/3Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage.In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed. The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to addre...
About
Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage.In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed. The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to addre...
Funding History
3Total raised: $50M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile